Acadia Pharmaceuticals | ACAD - Ordinary Share Capital


Acadia Pharmaceuticals reported $168.71M in Ordinary Share Capital for its fiscal quarter ending in September of 2025.





Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 168.71M 104K Sep/2025
ALKERMES USD 165.1M 49K Sep/2025
Alnylam Pharmaceuticals USD 131.79M 130.49M Sep/2025
Biogen USD 146.7M 200K Sep/2025
BioMarin Pharmaceutical USD 192.1M 97K Sep/2025
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Corcept Therapeutics USD 105.12M 164K Sep/2025
Cytokinetics USD 122.12M 2.52M Sep/2025
Eisai JPY 282.12M 0 Sep/2025
Eli Lilly USD 946.83M 354.23M Jun/2025
Incyte USD 196.13M 2.01M Sep/2025
J&J USD 2.41B 584K Sep/2025
Moderna USD 391M 2M Sep/2025
Neurocrine Biosciences USD 99.7M 700K Sep/2025
Pfizer USD 5.69B 1000K Sep/2025
Prothena USD 53.83M 53.29M Sep/2025
PTC Therapeutics USD 79.93M 554K Sep/2025
Sarepta Therapeutics USD 104.77M 7.06M Sep/2025
Ultragenyx Pharmaceutical USD 96.44M 88K Sep/2025
Vertex Pharmaceuticals USD 254M 2.29M Sep/2025